Wells Fargo Maintains Overweight on Merck & Co, Raises Price Target to $170

Benzinga Newsdesk www.benzinga.com Positive 76.3%

Neg 0% Neu 0% Pos 76.3%

Wells Fargo analyst Mohit Bansal maintains Merck & Co (NYSE:MRK) with a Overweight and raises the price target from $150 to $170.